LRAs United as a Novel Anti-HIV Strategy.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to HIV-1-infection
Related studies linked through entity extraction aliases.
Pertussis Immunization During Pregnancy & HIV Infection
- Status
- COMPLETED
- Phase
- N/A
Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations
- Status
- COMPLETED
- Phase
- N/A
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
- Status
- COMPLETED
- Phase
- PHASE4
Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)
- Status
- TERMINATED
- Phase
- PHASE3
Gut Microbiota and Immune Recovery
- Status
- UNKNOWN
- Phase
- N/A
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
- Status
- TERMINATED
- Phase
- PHASE2
HIV Persistence in Lymph Node and Peripheral Blood
- Status
- COMPLETED
- Phase
- N/A
IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment
- Status
- COMPLETED
- Phase
- N/A
Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fitness and Longevity in Exercise
- Status
- COMPLETED
- Phase
- NA
Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection
- Status
- UNKNOWN
- Phase
- NA
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
- Status
- COMPLETED
- Phase
- PHASE4
ANCHORS Study: UH2 Project
- Status
- COMPLETED
- Phase
- NA
The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients
- Status
- COMPLETED
- Phase
- NA
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
- Status
- TERMINATED
- Phase
- PHASE3
Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV
- Status
- COMPLETED
- Phase
- PHASE1
Pyridostigmine as Immunomodulator in People Living With HIV
- Status
- SUSPENDED
- Phase
- PHASE2
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
- Status
- COMPLETED
- Phase
- PHASE3
Improving Pregnancy Outcomes With Progesterone
- Status
- COMPLETED
- Phase
- PHASE3